Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte Inc (NQ: HUMA )

5.050 -0.100 (-1.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Humacyte Inc

< Previous 1 2 Next >
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA)
From Kirby McInerney LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
InvestorNewsBreaks – EF Hutton Serves as Placement Agent to Humacyte Inc.’s (NASDAQ: HUMA) $30M RDO
Via Investor Brand Network
Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox &amp; Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - October 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - (NewMediaWire) - October 21, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
NEW YORK, NY - (NewMediaWire) - October 19, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
From Pluristyx
Via Business Wire
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
Humacyte Third Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- 
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at the Cantor Global Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair 
From Humacyte, Inc
Via GlobeNewswire
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- 
From Humacyte, Inc
Via GlobeNewswire
Humacyte Second Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at Upcoming Investor Conferences in March
From Humacyte, Inc
Via GlobeNewswire
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
From Humacyte, Inc
Via GlobeNewswire
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
Thursday, December 15, 2022 @ 8:00 AM ET 
From Humacyte, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.